[Adjuvant systemic interferon alpha-2B treatment in treatment refractory anogenital Condylomata acuminata].
Despite different treatment modalities, resistance to treatment is observed in 4-15% of patients with anogenital condylomata acuminata. A total of 16 patients with resistant condylomata acuminata or extended infection affecting an area of more than 6 cm2 were treated with a prospectively defined therapy entailing laser treatment and adjuvant systemic interferon-alpha 2B (3 x 1 MU/day for 7 days). Of the 16 patients, 13 (81%) were in complete remission after an 8-month period of follow up. The typical side-effects of interferon were attenuated in 80% of cases by simultaneous paracetamol (3 x 500 mg/day). The combination of laser treatment and adjuvant systemic interferon-alpha 2B seems to be highly effective in the treatment of resistant or extended condylomata acuminata. At present, these results are being tested for significance in a prospectively randomized study.
Erpenbach
K
K
Abteilung Urologie, Bundeswehrzentralkrankenhaus Koblenz.
Derschum
W
W
von Vietsch
H
H
D000328:Adult; D001005:Anus Neoplasms / Q000601:surgery / Q000628:therapy*; D003131:Combined Modality Therapy; D003218:Condylomata Acuminata / Q000601:surgery / Q000628:therapy*; D004334:Drug Administration Schedule; D005500:Follow-Up Studies; D005834:Genital Neoplasms, Male / Q000601:surgery / Q000628:therapy*; D006801:Humans; D007279:Injections, Subcutaneous; D007370:Interferon Type I / Q000627:therapeutic use*; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D053685:Laser Therapy; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011994:Recombinant Proteins
D007370:Interferon Type I; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins
Adjuvant-systemische Interferon-alpha 2B-Behandlung bei therapieresistenten anogenitalen Condylomata acuminata.